IDE approval so full FDA approval would be further out. I'm still loading up, RCEL and CALZF can co-exist since one is deep wound and CALZF will also go after the hernia market which has nothing to do with RCEL. Breast augmentation is down the line as well, again no overlap with RCEL.
Market Data 
Markets 
AI
